Literature DB >> 7900657

Use of exercise technetium-99m sestamibi SPECT imaging to detect residual ischemia and for risk stratification after acute myocardial infarction.

M I Travin1, A Dessouki, T Cameron, G V Heller.   

Abstract

The clinical presentation, electrocardiographic findings, and technetium-99m sestamibi single-photon emission computed tomography (SPECT) imaging results of 134 consecutive patients who underwent nuclear exercise testing within 14 days of an acute myocardial infarction (AMI) were correlated with cardiac events over a 15 +/- 10-month follow-up. Whereas only 23 patients (17%) had chest pain and 31 (23%) had ischemic ST-segment depression during exercise, 94 (70%) had ischemia on SPECT (p < 0.001). On follow-up, 13 patients experienced a cardiac event: 7 were rehospitalized for unstable angina, 3 had recurrent AMI, and 3 died of cardiac causes. Ischemia on the sestamibi images identified 11 of these patients (85%), whereas chest pain identified only 3 (23%, p = 0.006), and electrocardiographic ischemia identified only 4 (31%, p = 0.017). The presence of either ischemia as seen on SPECT or defects in multiple vascular territories identified 12 patients (92%) with an event, including all who had cardiac death. By Cox regression analysis of clinical, stress, and image parameters, the number of ischemic defects on SPECT was the only significant correlate of a future event (chi-square = 4.62, p = 0.03), and patients with > or = 3 reversible sestamibi defects had an event rate of 38%. The extent of ischemia as seen on nuclear imaging remained a strong correlate (p = 0.008) of an event in the 54 patients (40%) who had received thrombolytic therapy. Thus, exercise technetium-99m sestamibi SPECT after AMI frequently reveals residual ischemia, and is better than clinical data, symptoms, and stress electrocardiographic data in identifying patients who will have a subsequent cardiac event.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7900657     DOI: 10.1016/s0002-9149(99)80650-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  24 in total

1.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

Review 2.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues.

Authors:  P Kailasnath; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 3.  Radionuclide imaging in risk assessment after acute coronary syndromes.

Authors:  J E Udelson; E J Flint
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 4.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

5.  The role of stress myocardial perfusion imaging in the risk stratification of patients with remote myocardial infarction.

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

6.  The troponin conundrum: clarification through stress myocardial perfusion SPECT.

Authors:  John J Mahmarian
Journal:  J Nucl Cardiol       Date:  2007-01       Impact factor: 5.952

Review 7.  Myocardial metabolic imaging in the acute care setting.

Authors:  John J Mahmarian
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

8.  Risk stratification after acute myocardial infarction: is it time to reassess? Implications from the INSPIRE trial.

Authors:  John J Mahmarian; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

9.  Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers.

Authors:  Mridula Rai; Alan W Ahlberg; Julianna Marwell; Waseem Chaudhary; John A Savino; Eric L Alter; Milena J Henzlova; W Lane Duvall
Journal:  J Nucl Cardiol       Date:  2016-02-22       Impact factor: 5.952

10.  Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: A randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction.

Authors:  John J Mahmarian; Leslee J Shaw; Gerald H Olszewski; Bradley K Pounds; Maria E Frias; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.